<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26071042</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>07</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-2105</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the National Cancer Institute</Title>
          <ISOAbbreviation>J Natl Cancer Inst</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">djv171</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/djv171</ELocationID>
        <Abstract>
          <AbstractText>T cell development and maturation involve a variety of defined and coordinated developmental stages under the control of a variety of signaling networks. They function as the major mediator in cell-based immunity that defends against pathogen infections and executes immune surveillance against tumor cells. Protein kinase B (PKB, also called Akt) is central to multiple signaling pathways and transduces extracellular signals to dictate cellular responses towards proliferation, migration, anti-apoptosis, and maintenance of metabolic homeostasis. Although the prosurvival function of PKB was thought to be responsible for most of the functions regulated by PKB, emerging evidence has started to dissect its role in immunomodulation. More importantly, hyperactivation of PKB in cancer stroma frequently occurs in patients treated clinically with targeted cancer therapies, where it acts as a key mediator involved in the trapping of host immune cells in the vicinity of tumors, which supports cancer cell invasion and the escape of cancer cells from host immune surveillance. Encouragingly, recent studies have shown that inhibition of PKB improves the recognition of cancer cells by the host immune system, indicating a potential clinical strategy to rekindle the suppressed host immune response through the specific targeting of PKB. In this review, we explore how PKB signaling contributes to T cell development and cellular immune responses and discuss the mechanistic roles that PKB plays in the creation of immunosuppressive conditions and the escaping of immune recognition in the microenvironment of cancer.</AbstractText>
          <CopyrightInformation>© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Gongda</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM). gongda.xue@unibas.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zippelius</LastName>
            <ForeName>Alfred</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wicki</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandalà</LastName>
            <ForeName>Mario</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Fengyuan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Massi</LastName>
            <ForeName>Daniela</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hemmings</LastName>
            <ForeName>Brian A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>06</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Natl Cancer Inst</MedlineTA>
        <NlmUniqueID>7503089</NlmUniqueID>
        <ISSNLinking>0027-8874</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515482">CCL22 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054422">Chemokine CCL22</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054422" MajorTopicYN="N">Chemokine CCL22</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056747" MajorTopicYN="Y">Immunomodulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26071042</ArticleId>
        <ArticleId IdType="doi">10.1093/jnci/djv171</ArticleId>
        <ArticleId IdType="pii">djv171</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
